Basic Information
Experimental Physicochemical Property
Not Available
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Factor | Reference |
|---|---|---|---|---|---|---|---|
| AUC | 4351.0 | ng.h/ml | 4351.0 | ng.h/ml | Capsule, PO, Oral; adults; | DRUGBANK | |
| Bioavailability | 34.0 | % | 34(32-37） | % | Capsule, PO, Oral; | DRUGBANK | |
| C Max | 788.0 | ng/ml | 788.0 | ng/ml | Capsule, PO, Oral; adults; | DRUGBANK | |
| T Max | 1.0 | h | 1 | h | Capsule, PO, Oral; adults; | DRUGBANK | |
| Tss | 72.0 | h | 3.0 | day | Capsule, PO, Oral; adults; | DRUGBANK | |
| Clearance | 98.0 | L/h | 98.0 | L/h | Average clearance; | DRUGBANK | |
| Volume of Distribution | 48.0 | L | 48.0 | L | Average volume of distribution; intravenous injection, IV; normal,healthy; | DRUGBANK | |
| Half-life | 2.9 | h | 2.9 | h | DRUGBANK | ||
| Eliminate Route | 58.0 | % | 58 | % | Faeces excretion; Oral single dose; normal,healthy; human, homo sapiens; | DRUGBANK | Eliminate Route | 39.0 | % | 39 | % | Urinary excretion; Oral single dose; normal,healthy; human, homo sapiens; | DRUGBANK | Eliminate Route | 2.9 | % | 2.9 | % | Faeces excretion; Oral single dose; normal,healthy; human, homo sapiens; Unchanged drug; | DRUGBANK | Eliminate Route | 7.8 | % | 7.8 | % | Urinary excretion; Oral single dose; normal,healthy; human, homo sapiens; Unchanged drug; | DRUGBANK |
| Protein Binding | 70.0 | % | ~70 | % | plasma proteins; human, homo sapiens; | Plasma Concentration → ; | DRUGBANK |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Frequency | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|---|
| Max dose for infants | 100.0 | mg/m2 | 100 | mg/m2 | PO, oral | q2d | Vitrakvi | larotrectinib | PDR |
| Max dose for children | 100.0 | mg | 100 | mg | PO, oral | bid | Vitrakvi | larotrectinib | PDR |
| Max dose for children | 100.0 | mg/m2 | 100 | mg/m2 | PO, oral | bid | Vitrakvi | larotrectinib | PDR |
| Max dose for adolescents | 100.0 | mg | 100 | mg | PO, oral | bid | Vitrakvi | larotrectinib | PDR |
| Max dose for adults | 100.0 | mg | 100 | mg | PO, oral | bid | Vitrakvi | larotrectinib | PDR |
| Max dose for geriatric | 100.0 | mg | 100 | mg | PO, oral | bid | Vitrakvi | larotrectinib | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1